A study of the effect of Carbonic Anhydrase inhibitor eye drops on vision outcomes in patients receiving macular hole repair surgery

Phase 2

• Conditions: Macular Hole; Eye - Diseases / disorders of the eye

• Registration Number: ACTRN12620001230943
• Lead Sponsor: Stephen Guest

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-11-17
• Last Update Posted: 24 May 2021

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

Patients with macular hole repair and residual submacular fluid at the 2 week postoperative timepoint

Exclusion Criteria

Allergy to carbonic anhydrase inhibitors
Underlying macular pathology other than macular hole ie age related macular degeneration or diabetic maculopathy or vein occlusion
Traumatic macular holes

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in LogMAR vision in operated eye.<br>[1 year after surgery];Proportion of eyes with total resolution of subretinal fluid assessed by Optical Coherence Tomography scanning[1 year after surgery]

Secondary Outcome Measures

Name	Time	Method
ogMAR visual acuity postoperatively[6 weeks, 3 months, 6 months 9 months out from surgery];Proportion of eyes with total resolution of subretinal fluid assessed by Optical Coherence Tomography scanning[Measured at 6 weeks, 3 months, 6 months, 9 months after surgery];Volume of fluid under macula.<br>This will be estimated by measuring (a)the average radius (r) of subfoveal fluid on OCT scanning and (b) the height (h) of the subfoveal fluid on OCT scanning. Using the formula 3.14 x r squared x h/3, the volume can be estimated.[6 weeks, 3 months,6 months, 9 months after surgery];Adverse effects of eye drops such as red eye, watering and irritation. There could be skin irritation if severe. A bitter or sour taste in the mouth is occasionally reported.<br>Patients would be encouraged to report to the principal investigator if symptoms occurred. Patients will be asked at each visit if the drops are being tolerated[At any time point in the first year after the surgery]